Author: [email protected]

Release – SKYX Will Deploy its Technologies During a Renovation of the Iconic 5-Star Hotel “The Mozart Prague” in the Capital of the Czech Republic Owned by Group OTT and Operated by Global Hospitality Leader Accor

Posted on by [email protected]

The Renovation is in Process and Will Include Rooms, Suites, Bars, Restaurants, Lobby, Ballroom, Spa, Gym, Meeting Rooms, Corridors, Among Other Hotel Areas

The Mozart Prague is Part of Group OTT’s European Hospitality Portfolio and is Managed and Operated by Accor, Renowned Global Hospitality Leader

SKYX’s Technologies Expansion Provides Additional Opportunities for Future Recurring Revenues through Interchangeability, Upgrades, AI Services, Monitoring, Subscriptions, Among Others

SKYX Technologies Reduces Up to 90% Time and Cost of Hotel Renovation or New Build and is Continuing Discussions with Additional Hotel Groups and Owners Regarding Utilization of its Game-Changing Technologies for Hotels and Buildings

MIAMI, June 10, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), an award-winning highly disruptive advanced smart home and AI platform technology company with over 100 U.S. and global pending and issued patents and a portfolio of 60 lighting and home décor websites, today announced it will deploy its advanced smart technologies as part of the comprehensive renovation of The Mozart Prague, an iconic 5-star hotel located in the heart of Prague, Czech Republic. The hotel will be managed and operated by renowned global hospitality leader Accor.

The Mozart Prague is owned by France-based Group OTT and operated by global hospitality leader Accor. The hotel forms part of Group OTT’s European hospitality portfolio and is currently undergoing an extensive renovation encompassing guestrooms, suites, restaurants, bars, public areas, meeting facilities, wellness amenities and other key hotel spaces.

The Mozart Prague iconic hotel sits in the Old Town district in the heart of the Czech capital and is well-located at the base of the Charles Bridge with picturesque views of Prague Castle. The Hotel dates to the 17th century and has a rich history, having hosted numerous celebrities such as Wolfgang Amadeus Mozart, Wagner, and more recently Vaclav Havel.

The hotel amenities and areas include bars, restaurants, ballroom, spa, and gym, among other hotel facilities.

During the course of renovation and new build, SKYX is expected to supply its advanced smart plug & play technologies comprising ceiling lighting, ceiling fans, recessed lights, down lights, EXIT signs, emergency lights, indoor and outdoor lights, wall lights among other advanced smart products.

For more than 35 years, France-based Group OTT has developed more than 250 buildings throughout Europe, including hotels, residential, and commercial projects valued at over $4 billion.

Jean-François Ott, Founder of Group OTT, said; “We are excited to include SKYX’s game-changing technologies for hotels and buildings during our Mozart Prague Hotel renovation. We expect to continue deploying SKYX’s technologies in additional European projects. By integrating SKYX’s technologies into these properties, we will cut significant time and cost while advancing the lifestyle and safety standards of our hotels and buildings.”

Rani Kohen, Founder and Executive Chairman of SKYX Platforms, said; “We are excited to deploy our technologies in an iconic and historical 5-star hotel such as Mozart Prague. Based on the time, cost saving, and advanced aspects of our technologies, and the value proposition for hotels, we expect to continue growing our builder and hotel segments in both the U.S. and Europe.”

For more information about Jean-François Ott and Group OTT click here: https://www.groupott.com/

For more information about SKYX click here: www.skyx.com

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced disruptive advanced-safe-smart home and AI platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://www.skyx.com/ or follow us on LinkedIn.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with third-party platforms or technologies; the Company’s ability to achieve positive cash flows; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Investor Relations Contacts:

Jeff Ramson
PCG Advisory
[email protected]

Ronald A. Both
Encore Investor Relations
[email protected]

Release – MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

Posted on by [email protected]

June 10, 2026 9:15am EDT

Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA

Potential breakthrough therapy holds substantial commercial opportunity in a projected $70 billion global non-small cell lung cancer market by 20301

CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the second U.S. clinical site in its Phase 2 THIO-101 expansion trial at Central Alabama Research in Homewood, Alabama. The expansion part of THIO-101 evaluates MAIA’s lead investigational therapy, ateganosine, a dual-action molecule incorporating telomere targeting and immunogenicity, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC) in patients who have previously failed treatment with checkpoint inhibitors (CPIs) and chemotherapy.

Parts A and B of the Phase 2 THIO-101 Phase 2 trial provided key inputs for MAIA’s market strategy by identifying optimal dosing for a well-defined patient population. The THIO-101 expansion trial is ongoing in Europe and Asia with 44 active sites in 6 countries along with 2 in the U.S. The additional data from the trial’s expansion may further support an accelerated approval filing with the FDA.

“Adding our second U.S. site reflects strong execution of our clinical strategy and continued momentum in the expansion of the THIO-101 trial,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “Broadening our site footprint enables more efficient patient enrollment as we advance the program under the FDA Fast Track designation and work toward upcoming interim data milestones.”

David J. Mooney, M.D., oncology physician at Central Alabama Research and principal investigator for THIO-101 in Alabama commented, “We look forward to bringing ateganosine treatment to our cancer center. There’s a large regional patient pool across the Southeast, including underserved and rural populations, that can greatly benefit from a novel therapy in this hard-to-treat NSCLC setting with very limited treatment options.”

In parallel with the Phase 2 clinical trial, MAIA is actively screening and enrolling patients in a pivotal Phase 3 clinical trial designed to assess overall survival for ateganosine sequenced with a CPI compared to investigator’s choice of chemotherapy in a 1:1 randomization of up to 300 patients. MAIA has received regulatory approval to screen patients in Taiwan, Turkey, select European Medicines Agency (EMA) countries, and Georgia.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About THIO-101 Phase 2 Clinical Trial

THIO-101 is a multicenter, open-label, dose finding Phase 2 clinical trial. It is the first trial designed to evaluate ateganosine’s anti-tumor activity when followed by PD-(L)1 inhibition. The trial is testing the hypothesis that low doses of ateganosine administered prior to cemiplimab (Libtayo®) will enhance and prolong immune response in patients with advanced NSCLC who previously did not respond or developed resistance and progressed after first-line treatment regimen containing another checkpoint inhibitor. The trial design has two primary objectives: (1) to evaluate the safety and tolerability of ateganosine administered as an anticancer compound and a priming immune activator (2) to assess the clinical efficacy of ateganosine using Overall Response Rate (ORR) as the primary clinical endpoint. The expansion of the study will assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous checkpoint inhibitor treatments (CPI) and chemotherapy. Treatment with ateganosine followed by cemiplimab (Libtayo®) has shown an acceptable safety profile to date in a heavily pre-treated population. For more information on this Phase II trial, please visit ClinicalTrials.gov using the identifier NCT05208944.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
[email protected]

Release – Snail Games Officially Launches Bellwright on Console and Unveiled New ARK Franchise Content at IGN Live 2026

Posted on by [email protected]

June 10, 2026 at 8:30 AM EDT

PDF Version

CULVER CITY, Calif., June 10, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, celebrates the launch of Bellwright on PlayStation and Xbox, extending one of the Company’s most successful recent titles to a broader audience and advancing its strategy of growing franchise reach through multi-platform distribution.

Bellwright is now available on PlayStation and Xbox, providing console players access to the open-world kingdom-building survival RPG that has already established a strong following on Steam.

Since its Early Access launch on Steam, Bellwright has achieved:

  • Over 1 million lifetime units sold
  • Over 46.4 million playtime hours
  • ‘Very Positive’ Steam rating based on over 18,000 user reviews globally.

Bellwright has been specifically optimized for consoles, with enhancements designed for large screen play and streamlined controls tailored to console audiences. The release broadens the game’s accessibility and positions the title to reach a wider segment of players beyond the PC market. As Snail Games continues to invest in both emerging and established franchises, the Company remains focused on expanding audience reach through platform growth, community engagement, and strategic content initiatives.

Bellwright’s console launch follows a strong weekend for Snail Games at IGN Live 2026. The Company showcased both Bellwright and the ARK franchise to thousands of attendees, media outlets, content creators, and industry partners. Bellwright was featured through developer interviews and a branded experiential activation that included a themed axe-throwing booth inspired by the game’s medieval setting. The title’s development team engaged directly with attendees to discuss the game’s evolution, future roadmap, and debuted a new trailer for the upcoming console release.

Alongside Bellwright, Studio Wildcard’s co-founder and ARK franchise co-creative director Jeremy Stieglitz took the stage at IGN Live to unveil a teaser for ARK Maker, a creation tool designed to expand community-generated content opportunities within the ARK ecosystem. Stieglitz also shared new details about ARK: The Animated Series, highlighting the continued expansion of the ARK universe ahead of Part 2’s return to Paramount+. With momentum continuing across the franchise, fans can stay tuned for even more ARK news later this month as Tides of Fortune and Genesis Ascended Part One prepare to launch.

Snail Games’ presence at IGN Live reflects its strategy to leverage major industry events to increase franchise awareness, strengthen community engagement, and support upcoming product launches across its portfolio.

For creators interested in collaborations please reach out to [email protected]

Snail Social Media: X | YouTube | Instagram | TikTok | Facebook

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/

Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this press release can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “may,” “predict,” “continue,” “estimate” and “potential,” or the negative of these terms or other similar expressions. These forward-looking statements include information about possible or assumed future results of Snail Games’ business, financial condition, results of operations, liquidity, plans and objectives. Forward-looking statements appear in a number of places in this press release and include, but are not limited to, statements regarding growing franchise reach through multi-platform distribution; highlighting the Company’s expanding portfolio at IGN Live 2026 while generating visibility ahead of several key initiatives; the anticipated upcoming console release of Bellwright; expanding community-generated content opportunities within the ARK ecosystem with ARK Maker; continuing to expand the ARK universe ahead of Part 2’s return to Paramount+; reinforcing ARK’s weight in the survival gaming genre; announcing more ARK news later this month as Tides of Fortune and Genesis Ascended Part One prepare to launch; leveraging major industry events to increase franchise awareness, strengthen community engagement, and support upcoming product launches across Snail Games’ portfolio; the Company continuing to invest in both emerging and established franchises while remaining focused on expanding audience reach through platform growth, community engagement, and strategic content initiative; and assumptions underlying any of the foregoing.

Further information on risks, uncertainties and other factors that could affect Snail Games’ financial results and business include Snail Games’ ability to strengthen its gaming portfolio’s visibility; Snail Games’ ability to expand and grow its franchise and increase its revenue; Snail Games’ ability to retain its key employees or maintain its Nasdaq listing; and the risks that are included in its filings with the Securities and Exchange Commission (the “SEC”) from time to time, including its annual reports on Form 10-K and quarterly reports on Form 10-Q filed, or to be filed, with the SEC. You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those expressed or implied in the forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on management’s beliefs and assumptions and on information currently available to Snail, and Snail does not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:
John Yi and Steven Shinmachi
Gateway Group, Inc.
949-574-3860
[email protected]

The Beachbody Company (BODI) – Noble Virtual Conference Highlights

Posted on by [email protected]


Wednesday, June 10, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble Virtual Conference. On June 3rd, the company presented at the Noble Virtual Conference. The presentation, conducted by Mark Goldston, Executive Chairman, and Brad Ramberg, CFO, highlighted the completion of its operational turnaround, a favorable product pipeline, and expanded distribution of its nutritional products in brick-and-mortar locations. A replay of the presentation is available here.

Enhanced Operating Model. Notably, over the past several years, the company has significantly lowered its revenue break-even level from $900 million in 2022 to roughly $180 million today. The improvement was largely driven by SG&A optimization and the elimination of multi-level marketing sales costs. The new model offers enhanced operating leverage, enabling profitability at lower revenue levels and improving its long-term outlook.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Snail (SNAL) – Noble Virtual Conference Highlights

Posted on by [email protected]


Wednesday, June 10, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Noble Virtual Conference. On June 3rd, Heidi Chow, CFO, and Peter Lin, Senior Manager FP&A, presented at the Noble Virtual Conference. The presentation highlighted strong Q1 operating results, a return to profitability, continued engagement on its core franchise, a busy 2026 release roadmap, and the advancement of its digital assets strategy. A replay of the presentation is available here.

ARK Franchise Durability. The ARK franchise is the company’s primary engine for engagement and monetization. Since its launch, it has produced roughly $1 billion in revenue, surpassed 113 million installs, and accumulated 4.4 billion hours of gameplay. Furthermore, the company highlighted new content releases as a driver of player engagement, with 42% of players averaging 376 hours of total playtime and a 57% lifetime paid DLC conversion rate. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Eledon Pharmaceuticals (ELDN) – Updates To Islet Cell Transplant Data Show Continued Insulin Independence

Posted on by [email protected]


Wednesday, June 10, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Islet Cell Transplant Data Presented At ADA Meeting. Eledon presented data at the American Diabetes Association Annual Meeting from its trial testing tegoprubart as an immunosuppressive in patients with Type 1 diabetes (T1D) receiving pancreatic islet cell transplants. These data update earlier presentations with additional patients and longer follow-up periods. After treatment, the patients were able to become insulin independent with no rejection episodes or treatment-related side effects.

Study Design. The trial enrolled 12 patients with Type 1 diabetes and poorly controlled glucose levels. Patients had diabetes for a mean duration of 33 years and a mean HbA1C of 8.0% at baseline. All received allogeneic pancreatic islet cell transplants with tegoprubart as part of their immunosuppression regimen instead of tacrolimus, a calcineurin inhibitor that is the standard of care in transplantation.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Figure Pays $717 Million for Kiavi as Blockchain Lending Moves From Concept to Scale

Posted on by [email protected]

The intersection of blockchain technology, artificial intelligence, and real estate lending just produced one of the more structurally interesting deals of 2026. Figure Technology Solutions (Nasdaq: FIGR), the blockchain-native capital marketplace for origination, funding, sale, and trading of tokenized financial assets, announced Wednesday it has entered into a definitive agreement to acquire Kiavi, the nation’s largest residential transition loan lender, for $717 million.

The transaction is structured in two parts. Figure is acquiring Kiavi’s technology platform and operating business directly. Simultaneously, a joint venture between Figure and Sixth Street, a global investment firm, will acquire Kiavi’s balance sheet assets — a structure that keeps Figure’s business model capital-light while still bringing the full operational and technological capability of Kiavi’s lending platform under its umbrella.

What Kiavi Actually Is

Founded in 2013 as LendingHome by Matt Humphrey and James Herbert, Kiavi has spent more than a decade building an AI-powered lending infrastructure specifically for residential real estate investors — the operators who buy distressed or underperforming properties, renovate them, and either sell or rent the finished product. It is the largest non-bank lender in the residential transition loan category, with more than $30 billion in funded loans across its history. In 2025 the company generated over $250 million in revenue and more than $100 million in EBITDA, establishing it as a profitable and scaled business rather than an early-stage platform.

The market Kiavi operates in is significant. The US housing stock is aging rapidly, with approximately $25 trillion in residential property estimated to require meaningful renovation or revitalization. Real estate investors are the primary mechanism through which that stock gets modernized — and they are heavily dependent on fast, reliable, technology-enabled lending to execute their business models at scale. Kiavi was built to serve exactly that demand.

What Figure Is Building

Figure’s core product is a blockchain-native marketplace where financial assets — primarily home equity loans and now residential transition loans — are originated, funded, sold, and traded on distributed ledger infrastructure. The appeal is operational: blockchain rails eliminate the layers of reconciliation, manual processing, and counterparty friction that characterize traditional loan markets, reducing costs and improving execution speed at scale.

The Kiavi acquisition adds $7 billion in annual first-lien loan volume to Figure’s marketplace and more than $100 million monthly to its Democratized Prime platform, where institutional lenders connect with investors. The first-lien mortgage market is approximately 25 times larger than the second-lien segment where Figure historically concentrated, making this a direct expansion into a far larger addressable market. With Kiavi integrated, Figure projects its consumer loan marketplace volume will reach more than 40% first-lien for full-year 2027.

The deal also serves as the launch platform for Adaptor, Figure’s newest AI product designed for fully agentic, agent-to-agent onboarding. Kiavi’s residential transition loan asset class will be the first to use Adaptor’s capabilities, automating the process through which borrowers and lenders connect on the platform without human intermediation.

Figure has confirmed the transaction reinforces its medium-term target of 60% EBITDA margins, reflecting the cost efficiencies expected from moving Kiavi’s loan assets onto blockchain infrastructure.

The Broader Fintech Signal

For investors tracking financial technology companies in the small and microcap space, the Figure-Kiavi deal is worth examining as a template for how fintech consolidation is evolving in 2026. The combination of blockchain infrastructure, AI-powered underwriting, and institutional capital partnerships through structures like the Sixth Street joint venture reflects a level of architectural sophistication that goes well beyond simple product acquisitions.

The tokenization of real-world financial assets onto blockchain rails is no longer a theoretical construct. At $717 million and $30 billion in funded loans, it is a transaction-scale reality.

GSK Pays $10.6 Billion for Nuvalent in Its Largest Acquisition in Over a Decade

Posted on by [email protected]

The biotech acquisition market just recorded one of its most significant transactions of 2026. GSK (LSE/NYSE: GSK) announced Tuesday it has entered into a definitive agreement to acquire Nuvalent Inc. (Nasdaq: NUVL), a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company focused on precision oncology, for $10.6 billion in an all-cash tender offer at $124 per share. The price represents a 40% premium to Nuvalent’s last closing price and a 26% premium to its 30-day volume-weighted average price. Net of cash acquired, GSK’s aggregate investment is approximately $9.4 billion.

Nuvalent shares surged nearly 40% in premarket trading. GSK shares slipped approximately 1.5% in London as the market processed the scale of the commitment.

The deal marks GSK’s largest acquisition in more than a decade and the first major transaction under the leadership of new CEO Luke Miels, who took over from Emma Walmsley in January 2026. It signals a deliberate strategic pivot — GSK is moving aggressively into oncology as it confronts patent expiration pressures on established products, including its blockbuster shingles vaccine Shingrix, and seeks to close the gap with rival AstraZeneca, whose oncology sales accounted for 44% of total revenue last year.

What GSK Is Actually Buying

Founded in 2017, Nuvalent has built its pipeline around precisely targeted therapies for non-small cell lung cancer, one of the largest and most commercially significant oncology indications globally. Its two lead assets are zidesamtinib, a ROS1 inhibitor, and neladalkib, an ALK inhibitor — both of which have received FDA Breakthrough Therapy Designation and Orphan Drug Status and are currently under active FDA review.

FDA target decision dates are September 18, 2026 for zidesamtinib and November 27, 2026 for neladalkib. Subject to approval, both drugs are expected to launch before year-end 2026, with combined peak annual sales potential estimated at $3 billion to $4 billion. The pipeline also includes NVL-330, a potential best-in-class HER2 inhibitor currently in Phase I trials for HER2-altered non-small cell lung cancer, adding a third growth platform beyond the two near-term approvals.

GSK expects the acquisition to be accretive to sales and core operating profit in 2027 and accretive to core earnings per share in 2029, inclusive of synergies and pipeline reprioritization. The company plans to complement Nuvalent’s lung cancer platform with its own Ris-Rez B7-H3 antibody-drug conjugate, creating an integrated oncology franchise in one of the sector’s highest-priority therapeutic areas.

The Small Cap Biotech Signal

GSK paying $10.6 billion for a clinical-stage company with no approved products and no commercial revenue carries a specific and powerful message for small and microcap biotech investors. The premium reflects the value of FDA Breakthrough Therapy Designation, validated mechanism of action, late-stage regulatory visibility, and a clearly defined commercial opportunity in a large patient population.

The broader biotech M&A environment is accelerating. Patent cliffs across major pharmaceutical companies are creating urgency to acquire external innovation, and the pipeline of clinical-stage companies with validated oncology assets in the sub-$2 billion market cap range remains deep. When large pharma assigns a $10.6 billion value to a pre-revenue biotech, it resets the reference point for how the market values similar-stage assets across the sector.

Upon completion of the tender offer and merger, Nuvalent common stock will be delisted from Nasdaq.

Summit Midstream Corp (SMC) – Double E Momentum Enhances Earnings Visibility

Posted on by [email protected]


Tuesday, June 09, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

George Proost, Research Intern, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Double E Expansion Gains Commercial Traction. Summit Midstream announced additional long-term transportation commitments on its Double E Pipeline, bringing open season commitments to 250 MMcf/d and total contracted capacity to approximately 1.9 Bcf/d. Demand has exceeded available expansion capacity, prompting the company to extend its open season through June 30, 2026, while continuing negotiations with prospective shippers. Management remains on track to reach a final investment decision by the end of summer and has secured key compressor equipment to support a targeted late-2028 in-service date.

Strong Demand Supports Capacity Expansion. The Double E Compression Expansion would increase pipeline capacity by approximately 50%, from 1.6 Bcf/d to 2.4 Bcf/d, further strengthening its role as a key natural gas takeaway system in the Delaware Basin. In addition to the 250 MMcf/d of binding commitments secured, Summit holds a firm option agreement for another 200 MMcf/d and continues discussions with shippers whose interest exceeds available capacity. The strong commercial response reduces project risk and underscores continued demand for Permian Basin natural gas infrastructure.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Graham (GHM) – Building Momentum Ends in a Record Year

Posted on by [email protected]


Tuesday, June 09, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Fiscal 2026 was another year of strong execution and continued progress against the strategic objectives Graham management has outlined. The Company generated record annual revenue, record orders, and record backlog, ending the year with a book-to-bill of 1.5x. These results reflect the strength of Graham’s diversified business model and the long-term demand environment across its core markets, in our view.

FY4Q and Full Year ’26 Results. Fourth quarter revenue was a record $67.1 million, up 13% y-o-y. Gross margin declined to 22.7% from 27% last year, mostly due to mix. Quarterly adjusted EBITDA totaled $6.8 million versus $7.7 million last year, while adjusted net income was $3.7 million, or $0.33/sh, compared to $4.8 million and $0.43/sh in 4Q25. Full-year revenue was a record $245.3 million, up 17%, gross margin was 23.5% versus 25.2%, adjusted EBITDA was $26 million, up from $22.5 million, and adjusted net income was $16 million, or $1.40/sh, compared to $13.7 million, or $1.24/sh, in FY 2025. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Alliance Resource Partners (ARLP) – ARLP Expands Royalties Platform with AllDale Acquisition

Posted on by [email protected]


Tuesday, June 09, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

George Proost, Research Intern, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Expanded Oil and Gas Royalties Platform. Alliance Resource Partners executed definitive agreements to acquire general and limited partner interests in AllDale Minerals III and IV for approximately $206.2 million, subject to customary closing price adjustments. The transaction will increase ARLP’s economic ownership from roughly 5 percent to 61 percent, while providing operational control through 100 percent ownership of the non-economic general partner interests. The agreements provide for an effective date of April 1 with the transaction is expected to close in July.

Development Upside. The acquired portfolio includes approximately 48,500 net royalty acres and generates meaningful production and royalty income, with the Permian Basin accounting for more than half of first-quarter royalty revenue. The acquisition provides development upside by increasing ARLP’s exposure to new well activity in key basins and establishing exposure to the Haynesville Shale, which is expected to benefit from growing U.S. LNG export demand.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Novanta Pays Up to $1.45 Billion for Riverpoint Medical as the Minimally Invasive Surgery Market Heats Up

Posted on by [email protected]

Novanta Inc. (Nasdaq: NOVT), a Boston-based technology partner to medical and industrial original equipment manufacturers, announced Tuesday it has entered into a definitive agreement to acquire Riverpoint Medical from private equity firm Arlington Capital Partners in a deal valued at up to $1.45 billion. The transaction includes $1.2 billion in upfront cash consideration at closing, expected in the third quarter of 2026, and a $250 million milestone payment scheduled for the first quarter of 2027, subject to customary regulatory approvals and closing conditions.

The acquisition is immediately accretive to Novanta’s revenue growth, adjusted gross margins, adjusted EBITDA margins, adjusted diluted earnings per share, and operating cash flows. Critically, it doubles Novanta’s recurring medical consumables revenue in a single transaction — a portfolio transformation that meaningfully reduces the business cyclicality that has historically characterized the company’s industrial revenue exposure.

What Riverpoint Medical Brings to the Table

Founded in 2008 and headquartered in Portland, Oregon, Riverpoint Medical is a developer, designer, and manufacturer of highly engineered minimally invasive surgical consumables and instruments. The company’s core competency is advanced surgical fiber technology — proprietary implants and constructs used across high-growth end markets including sports medicine, trauma, and cardiovascular surgery. Riverpoint operates as a private-label supplier to strategic OEM partners, manufacturing products that carry those partners’ brands rather than its own, embedding itself deeply into customer supply chains in a way that generates durable, recurring revenue relationships.

That business model is precisely what makes the acquisition strategically coherent for Novanta. Medical consumables consumed during surgical procedures are replaced with every case, creating a revenue stream that is predictable, recurring, and largely insulated from the capital equipment budget cycles that create volatility in Novanta’s industrial segment.

Riverpoint operates manufacturing facilities across North America and has invested in international production capacity, including a facility in Costa Rica’s Zona Franca Coyol free trade zone. Novanta has signaled a clear intention to accelerate Riverpoint’s European expansion by leveraging its existing international OEM customer relationships — creating a near-term revenue lever that organic growth alone could not have achieved as quickly.

The Minimally Invasive Surgery Tailwind

The strategic backdrop for this deal is straightforward. Minimally invasive surgery has been one of the most consistently high-growth segments in medical device markets for over a decade, driven by an aging global population, preference for shorter recovery times, reduced hospital stay costs, and continuous procedural innovation. The sports medicine and orthopedic segments in particular have seen sustained volume growth as active aging and sports participation rates support a durable patient pipeline.

For small and microcap investors tracking the medical device and surgical technology space, the Novanta-Riverpoint deal is a signal that strategic acquirers continue to assign premium valuations to companies with recurring revenue models, proprietary technology, and deep OEM integration in high-volume surgical end markets. Arlington Capital Partners built Riverpoint through targeted acquisitions, including the purchase of CP Medical in June 2024, before achieving a full exit to a public company buyer at a significant return.

The structure of the deal — with $250 million in contingent milestone consideration — reflects the forward growth expectations embedded in the transaction and aligns both parties around Riverpoint’s continued performance post-close.

Iran and Israel Exchanged Strikes Over the Weekend. Markets Are Climbing Anyway

Posted on by [email protected]

The Middle East ceasefire that had been pushing oil prices lower and lifting consumer-facing small caps out of a months-long margin squeeze took a significant blow over the weekend. Iran and Israel exchanged military strikes in a direct escalation that threatened to unravel the fragile framework that US and Gulf state diplomats had been carefully assembling since late May. Oil prices rose sharply on the news. The geopolitical risk premium that had been slowly draining out of the market snapped back in an instant.

And yet Monday morning, US equity markets are climbing. The Nasdaq is rebounding from Friday’s steep losses. The Russell 2000 is recovering alongside it. Investors looked at the weekend’s escalation and largely decided to keep buying.

The Pattern That Keeps Repeating

This is not the first time the market has absorbed a Middle East shock and moved higher. Throughout the Iran conflict that began February 28, equity markets have repeatedly demonstrated a capacity to digest geopolitical escalation faster than most historical precedents would suggest. Each time the news cycle generates a fresh crisis — strikes, drone exchanges, ceasefire collapses, renewed negotiations — the initial market reaction has been sharp and the recovery has followed within sessions rather than weeks.

The explanation is not that investors are ignoring the conflict. It is that the underlying economic data keeps coming in strong enough to compete with the geopolitical noise for the market’s attention. Last Friday’s May payroll report showed 172,000 jobs added against expectations of just 88,000 — nearly double the consensus estimate. Consumer spending data has held up. Corporate earnings, particularly in AI infrastructure and energy, have been robust. The domestic economy that small cap companies are most exposed to has continued to perform even as the broader geopolitical environment remains unsettled.

The Oil Variable

The weekend escalation immediately reversed some of the oil price relief that had been building since late May when a draft memorandum of understanding between the US and Iran first circulated. WTI crude, which had pulled back toward $90 on ceasefire optimism, moved higher Monday as the market repriced the probability of a near-term resolution. The Strait of Hormuz situation, which we have been tracking closely since the conflict began, remains the central variable. Any sustained closure or re-escalation of maritime disruption would send prices back toward the levels that were squeezing small cap consumer and logistics companies through most of April and May.

The Iran-Israel dimension adds a new layer of complexity to what had been framed primarily as a US-Iran negotiation. Israeli strikes on Iranian territory and Iranian retaliatory fire represent a direct bilateral military exchange that operates on a different diplomatic track than the economic negotiations brokered through Gulf intermediaries.

What Resilient Markets Are Telling Small Cap Investors

The market’s repeated ability to recover from geopolitical shocks carries a specific message for investors in the sub-$2 billion market cap space. Domestically focused small cap companies generate approximately 80% of their revenue inside the United States. Their fundamental performance is far more tied to the strength of the domestic labor market, consumer spending patterns, and the rate environment than to the outcome of overseas conflicts — unless those conflicts translate into sustained inflation through energy prices.

That is the key variable to watch. If the Iran-Israel escalation remains contained and does not materially disrupt oil flows through the Strait of Hormuz, the market’s Monday morning recovery is likely to hold. If it escalates into a broader regional event that pushes WTI back above $100 and reignites inflation expectations, the calculus for the Federal Reserve and for small cap borrowing costs changes quickly.

For now the market has made its read. The Russell 2000 is green on Monday morning despite a weekend of serious geopolitical news. That is a data point worth noting.